ecause the outcome of tricuspid valve replacement (TVR) is relatively poor, most tricuspid valve surgery is repair procedures. As a result, the experience of prosthetic valve replacement in the tricuspid position is limited and the optimal choice of replacement valve is still controversial. Generally, bioprostheses have excellent antithrombogenic characteristics with relatively greater durability, and many recommend this choice for TVR. 1-3 On the other hand, satisfactory results with the newly developed bileaflet mechanical valve have been demonstrated, 4-7 though higher levels of anticoagulation were required. In particular, when a patient already has mechanical prostheses in the aortic and/or mitral position, a more durable mechanical valve may be a better choice than a bioprosthesis, because such patients will require anticoagulation regardless of the kind of prosthesis used in the tricuspid position. Additionally, the patient often has had multiple previous valve surgeries, so any future potential surgery should be avoided because of the high surgical risk.
A more durable mechanical valve may be a better choice for the tricuspid position than a bioprosthesis when the patient already has mechanical prosthesis in the left side of the heart. Eleven cases of triple valve replacement (total follow-up period, 49.5 patient years), all with mechanical valves, are reviewed to assess optimal valve selection. Nine patients had undergone a total of 12 previous cardiac surgeries. Three patients died in hospital (27.3%), but there were no late deaths among the survivors. Two cases of valve thrombosis in the tricuspid position occurred (linearized incidence: 4.04%/patient years) and 1 of these required reoperation. Because of this high incidence of valve thrombosis, the bileaflet mechanical valve is not considered to be the best choice. Even if mechanical valves are implanted in the left side of the heart, a bioprosthesis may be a better choice at the tricuspid position. ( 
Surgical Techniques and Postoperative Anticoagulation Therapy
All operations were carried out through a median sternotomy incision with standard cardiopulmonary bypass. Myocardial protection was achieved with cold crystalloid or cold blood cardioplegia. The MVR was performed first, followed by the AVR and then the TVR while the aorta was cross-clamped. The tricuspid prosthesis was implanted in the antianatomical position.
Intravenous administration of dipyridamole was initiated 6 h after surgery and heparin was started on the first operative day and continued until stable anticoagulation was obtained by oral medication, consisting of warfarin and platelet inhibitor (dipirydamole 300 mg or aspirin 100 mg daily), which was usually instituted within 72 h of surgery. The thrombo-test level was kept at around 20% or the prothrombin time level of 2.0-2.5 of the control value.
Statistical Analysis
The Kaplan-Meier method was used for calculating the actuarial probability of survival and morbidity events. Results are expressed as the mean ± SD.
Results
There were 3 hospital deaths (27.3%) after the TVR and concomitant procedures: prosthetic valve endocarditis on the Bjork-Shiley aortic valve, low cardiac output because of poor cardiac protection, and multiple organ failure (Table3). The other 8 patients survived the operation, were discharged and followed up for 9 months to 17.2 years (mean, 4.5±4.1 years; total follow-up period, 49.5 patient years). There were no late deaths among the survivors (Fig 1) .
Before operation, 9 patients were in New York Heart Association (NYHA) class III and 2 were in class IV. At the time of last follow-up of the survivors, 5 patients were NYHA class I and 3 in class II (Fig 2) . The echo Doppler study at the last follow-up showed all normally functioning prostheses demonstrating clinically acceptable hemodynamic performance (Table 4) .
No patients developed systemic or pulmonary embolism, but despite of appropriate anticoagulation therapy, 2 cases of valve thrombosis, diagnosed by cineradiography and Doppler echocardiography, occurred on the SJM valve at the tricuspid site, 2 months and 3 years postoperatively (Fig 3) . The linearized incidence of valve thrombosis was 4.04%/patient·year. One patient was successfully treated by thrombolysis with urokinase, but the other underwent replacement of the SJM tricuspid valve with a CarpentierEdwards supra-annular porcine valve 36 months after simultaneous triple valve replacement because thrombolysis therapy was unsuccessful (Fig 4) . No valve thrombosis was seen in the aortic or mitral sites. One case of prosthetic valve endocarditis occurred in the aortic position (Bjork-Shiley valve) and this patient died. However, no prosthetic valve endocarditis was seen in tricuspid position.
No patients had hemorrhagic complications related to the anticoagulant therapy.
Discussion
Most patients who require triple valve replacement have had a long clinical course, severely compromised cardiac function and myocardial damage. Therefore, even in recent years, triple valve replacement is associated with a high risk and a late mortality of 12-37%. [8] [9] [10] [11] [12] [13] The early mortality rate of 27.3% of the present study is comparable with those reports, and the absence of late death in the perioperative survivors after triple valve replacement was similar to the result in patients surviving single valve replacement. 14 This indicates that triple valve replacement will provide a preferable outcome for severe multiple valve disease if the patient can survive the early postoperative period.
Although the TVR is justified for severe tricuspid disease to obtain better life expectancy, the optimal prosthetic valve is still controversial, particularly for the tricuspid position. Some older mechanical prostheses, such as disc or ball valves, are prone to dysfunction by pannus formation or thrombosis. [15] [16] [17] Therefore, many have advocated the use of bioprostheses for TVR 1,2,18-20 because (1) no anticoagulation is required compared with the mechanical valve, which requires a high level of anticoagulation, (2) there are fewer valve-related complications, including thrombotic events, and (3) greater durability is anticipated because of lower pressure and lower stress in the right heart than in the left heart. With the bioprosthesis for MVR, at 10 years the freedom from tissue failure is 81-82% and from valve reoperation is 76-78%. 21, 22 In contrast to these results, the actuarial freedom from structural valve failure of bioprosthetic TVR at 10 years was 94% and from valve-related complication was 78%. 2 However, there are other opinions regarding the durability. Rizzoli et al reported that the bioprostheses are not superior to mechanical ones in the long term because of the high rate of degeneration, particularly after 7 years. 6 Echocardiography demonstrated that 5 years post operation 35% of patients have subclinical bioprosthesis dysfunction. 12 According to Kobayashi et al, the actuarial rates of freedom from bioprosthesis stenosis and regurgitation at 10 years were as high as 46% and 51%, respectively. 23 Therefore, some institutions actively select the new bileaflet mechanical valve rather than a bioprosthsis. Van Nooten et al demonstrated that the new mechanical prostheses had a better outcome than the bioprosthesis if the follow up was longer than 7 years, though there was no difference until 7 years after valve implantation. 5 They conclude that the current bileaflet mechanical valve is preferable for young patients with a good long-term prognosis.
We selected bileaflet mechanical valves for TVR for the following reasons: (1) we had experienced favorable results of valve function and anti-thrombogenicity in the aortic and mitral positions, 24 (2) our initial results of TVR with an SJM valve were encouraging, 25 and (3) the patients who require TVR have often had a long clinical course and multiple previous valve surgeries, so it was considered that the durable mechanical valve would be advantageous because of a reduced potential for reoperation. Unfortunately, we could not find any clear advantage of the mechanical valve for TVR from this study. A rate of thrombotic events of 4.04%/patient·year was worse than we anticipated and must be associated with the internal morphology of the right ventricle, which could potentially directly infringe on the mechanism of mechanical valve at the tricuspid site. 18, 21 However, except for the valve thrombosis, the results with regard to function, hemodynamics and valve-related complications were satisfactory. A review of 23 of our current patients who received 25 bileaflet valves for TVR, with or without other valve replacement, also showed a high valve thrombosis rate (6 cases of valve thrombosis; 2.9%/patient·year). 26 Because of this relatively high valve-related complication, we recently changed our policy and now use the bioprosthesis as our first choice for TVR. Although the present study could not demonstrate any clear advantage of the mechanical prosthesis, it is also true that we do not have enough experience to adequately evaluate the feasibility of the bioprostheses for TVR. However, we believe that the bioprostheses, which are less durable but have better antithrombogenic characteristics, may be a better choice even if the patient has mechanical valves in the left side of the heart. It goes without saying that it is too early to conclude that the mechanical valve is not optimal for TVR without comparative data with bioprostheses.
In summary, the bileaflet mechanical valve prosthesis for TVR in triple valve replacement had a relatively high incidence of valve thrombosis. It is too early to conclude, but this study suggests that a mechanical prosthesis is not the optimal choice in the tricuspid position, even if mechanical valves are implanted in the left heart. A bioprosthesis may be a preferable alternative.
